Relapse Rates, Time-to-Flare, and Biomarker Predictors following Omalizumab Gradual De-Escalation versus Abrupt Discontinuation in Controlled Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Cohorts
International Archives of Allergy and Immunology · 15.10.2026 · 1-1
DOI: 10.1159/iaa/adfag017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Archives of Allergy and Immunology, online erschienen am 15.10.2026. Verfasst von Muhammed Şah Doğan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Clinical Immunology, Faculty of Medicine, Erciyes University, Kayseri, Turkey, m.sahdogan@yyu.edu.tr. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Introduction
Omalizumab is highly effective in H1-antihistamine refractory chronic spontaneous urticaria (CSU), but disease relapse frequently follows treatment discontinuation. Whether gradual de-escalation reduces recurrence rates compared with abrupt cessation remains controversial.
Methods
Following PRISMA 2020 guidelines, PubMed, EMBASE, Web of Science, and Cochrane Library were searched through April 2026 for randomized controlled trials and observational cohorts evaluating omalizumab withdrawal in controlled CSU. Random-effects proportion meta-analysis (DerSimonian-Laird logit transformation) determined pooled relapse rates. Subgroup differences were tested via Cochran’s Qb statistic.
Results
Eleven primary studies yielding 13 independent study arms (evaluable N = 1,382) met inclusion criteria (total reviewed population N = 5,130). The overall pooled post-discontinuation relapse rate was 39.5% (95% CI: 30.1%–49.7%; I2 = 91.5%). Gradual de-escalation achieved a significantly lower pooled relapse rate compared with abrupt discontinuation (31.2% [95% CI: 20.3%–44.7%] vs. 48.9% [95% CI: 37.0%–61.0%], Qb = 8.12, df = 1, p = 0.004). Notably, dose reduction (150 mg every 4 weeks) yielded the lowest pooled relapse rate at 23.3% (95% CI: 9.2%–47.6%; I2 = 50.4%), outperforming interval extension (33.6%). Concomitant angioedema was an independent risk factor for relapse (multivariate OR = 2.399, p = 0.004), whereas gradual de-escalation was protective (multivariate OR = 0.373, p = 0.005).
Conclusion
Gradual omalizumab de-escalation significantly reduces post-discontinuation relapse rates compared with abrupt cessation in controlled CSU. Stepping down dose density to 150 mg every 4 weeks provides superior remission stability compared with interval extension or abrupt stopping, serving as a primary clinical recommendation for treatment optimization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Allergy and Clinical Immunology, Faculty of Medicine, Erciyes University, Kayseri, Turkey, m.sahdogan@yyu.edu.tr.
- Department of Dermatology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey.
- Department of Internal Medicine, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkey.
Zitieren
APA
Doğan, M. Ş., Yıldız, S., & Tunç, R. (2026). Relapse Rates, Time-to-Flare, and Biomarker Predictors following Omalizumab Gradual De-Escalation versus Abrupt Discontinuation in Controlled Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Cohorts. International Archives of Allergy and Immunology, 1-1. https://doi.org/10.1159/iaa/adfag017
Vancouver
Doğan MŞ, Yıldız S, Tunç R. Relapse Rates, Time-to-Flare, and Biomarker Predictors following Omalizumab Gradual De-Escalation versus Abrupt Discontinuation in Controlled Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Cohorts. International Archives of Allergy and Immunology. 2026:1-1. doi:10.1159/iaa/adfag017
BibTeX
@article{Doan2026,
author = {Doğan, Muhammed Şah and Yıldız, Sezgin and Tunç, Ruhat},
title = {Relapse Rates, Time-to-Flare, and Biomarker Predictors following Omalizumab Gradual De-Escalation versus Abrupt Discontinuation in Controlled Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Cohorts},
journal = {International Archives of Allergy and Immunology},
year = {2026},
pages = {1--1},
doi = {10.1159/iaa/adfag017}
}
EUVIMED